PMC:7696151 / 110658-111184 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-PubTator

    {"project":"LitCovid-PubTator","denotations":[{"id":"4064","span":{"begin":68,"end":76},"obj":"Species"},{"id":"4065","span":{"begin":469,"end":476},"obj":"Species"},{"id":"4066","span":{"begin":498,"end":505},"obj":"Species"},{"id":"4190","span":{"begin":92,"end":100},"obj":"Disease"},{"id":"4191","span":{"begin":270,"end":275},"obj":"Disease"},{"id":"4192","span":{"begin":382,"end":391},"obj":"Disease"},{"id":"4193","span":{"begin":422,"end":431},"obj":"Disease"},{"id":"4194","span":{"begin":489,"end":493},"obj":"Disease"},{"id":"4195","span":{"begin":517,"end":525},"obj":"Disease"}],"attributes":[{"id":"A4064","pred":"tao:has_database_id","subj":"4064","obj":"Tax:9606"},{"id":"A4065","pred":"tao:has_database_id","subj":"4065","obj":"Tax:9606"},{"id":"A4066","pred":"tao:has_database_id","subj":"4066","obj":"Tax:9606"},{"id":"A4190","pred":"tao:has_database_id","subj":"4190","obj":"MESH:C000657245"},{"id":"A4191","pred":"tao:has_database_id","subj":"4191","obj":"MESH:D003371"},{"id":"A4192","pred":"tao:has_database_id","subj":"4192","obj":"MESH:D011014"},{"id":"A4193","pred":"tao:has_database_id","subj":"4193","obj":"MESH:D011014"},{"id":"A4194","pred":"tao:has_database_id","subj":"4194","obj":"MESH:D005076"},{"id":"A4195","pred":"tao:has_database_id","subj":"4195","obj":"MESH:D006261"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Chen et al. (2020) [6] Randomized, parallel-group clinical trial62 patients suffering from COVID-19 HCQ group -\u003e 400 mg/day HCQControl group -\u003e SOCDay 5 Body temperature recovery time in the HCQ group was shorter than the control group (2.2 vs. 3.2 days, p = 0.0008).Cough remission time was significantly decreased in the HCQ group (2.0 vs. 3.1 days, p = 0.0016).Improvement of pneumonia in HCQ group (80.6% vs. 54.8%)Pneumonia absorption in HCQ group (61.3%) One patient developed a rash.One patient reported a headache."}

    LitCovid-PD-HP

    {"project":"LitCovid-PD-HP","denotations":[{"id":"T262","span":{"begin":270,"end":275},"obj":"Phenotype"},{"id":"T263","span":{"begin":382,"end":391},"obj":"Phenotype"},{"id":"T264","span":{"begin":422,"end":431},"obj":"Phenotype"},{"id":"T265","span":{"begin":517,"end":525},"obj":"Phenotype"}],"attributes":[{"id":"A262","pred":"hp_id","subj":"T262","obj":"http://purl.obolibrary.org/obo/HP_0012735"},{"id":"A263","pred":"hp_id","subj":"T263","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A264","pred":"hp_id","subj":"T264","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A265","pred":"hp_id","subj":"T265","obj":"http://purl.obolibrary.org/obo/HP_0002315"}],"text":"Chen et al. (2020) [6] Randomized, parallel-group clinical trial62 patients suffering from COVID-19 HCQ group -\u003e 400 mg/day HCQControl group -\u003e SOCDay 5 Body temperature recovery time in the HCQ group was shorter than the control group (2.2 vs. 3.2 days, p = 0.0008).Cough remission time was significantly decreased in the HCQ group (2.0 vs. 3.1 days, p = 0.0016).Improvement of pneumonia in HCQ group (80.6% vs. 54.8%)Pneumonia absorption in HCQ group (61.3%) One patient developed a rash.One patient reported a headache."}

    LitCovid-sentences

    {"project":"LitCovid-sentences","denotations":[{"id":"T754","span":{"begin":0,"end":526},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Chen et al. (2020) [6] Randomized, parallel-group clinical trial62 patients suffering from COVID-19 HCQ group -\u003e 400 mg/day HCQControl group -\u003e SOCDay 5 Body temperature recovery time in the HCQ group was shorter than the control group (2.2 vs. 3.2 days, p = 0.0008).Cough remission time was significantly decreased in the HCQ group (2.0 vs. 3.1 days, p = 0.0016).Improvement of pneumonia in HCQ group (80.6% vs. 54.8%)Pneumonia absorption in HCQ group (61.3%) One patient developed a rash.One patient reported a headache."}